Bloomberg News

Abbott’s Humira Wins European Approval for Ulcerative Colitis

April 11, 2012

Abbott Laboratories (ABT:US) said the European Commission approved its Humira injection for moderately to severely active ulcerative colitis in adults who haven’t responded well to conventional treatment.

The decision makes Humira the first self-injectable biologic therapy for these patients, Abbott Park, Illinois-based Abbott said today in a statement. It’s the seventh approved use for the drug since it was first cleared in the European Union in 2003, the company said.

Ulcerative colitis is a chronic inflammatory bowel disease that causes ulcers in the colon and may affect as many as 1.2 million people in the EU, according to Abbott.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net


Best LBO Ever
LIMITED-TIME OFFER SUBSCRIBE NOW

Companies Mentioned

  • ABT
    (Abbott Laboratories)
    • $43.38 USD
    • 0.48
    • 1.11%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus